InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint

MT Newswires Live

07/28

InnoCare Pharma (HKG:9969, SHA:688428) said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.

The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.

The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.

The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2654073308"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2654073308\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2654073308?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 13:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654073308","market":"fut","top_or_hot":-1,"title":"InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint","media":"MT Newswires Live","content":"<html><body><p> InnoCare Pharma (HKG:9969, SHA:688428) said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.</p><p>The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.</p><p>The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.</p><p>The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoCare Pharma's Phase III Trial of Fadeucravacitinib Meets Primary Endpoint\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-07-28 13:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> InnoCare Pharma (HKG:9969, SHA:688428) said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.</p><p>The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.</p><p>The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.</p><p>The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09969","symbol_name":"諾誠健華","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2654073308","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654073308","pubTimestamp":1785215442,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"InnoCare Pharma  said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","09969":"诺诚健华","BK4134":"信息科技咨询与其它服务","BK0239":"医药制造","III":"信息服务","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"诺诚健华Fadeucravacitinib III期试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":0.9,"III":1.5,"09969":0.9},"content_text":"InnoCare Pharma (HKG:9969, SHA:688428) said the Phase III clinical trial of fadeucravacitinib met its primary endpoint, according to a Hong Kong bourse disclosure on Monday.The pharmaceutical company's Hong Kong shares rose 1% during Tuesday's midday trade.The drug was tested as a treatment for patients with moderate-to-severe plaque psoriasis.The drug's safety profile was consistent with previous clinical studies and no new safety signals were identified. Results from the study will be presented at upcoming international scientific congresses and in medical journals.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}